AI has learned the ins and outs of proteins. Gene editing gives scientists control of life’s molecular machinery. Together they could lead to a revolution in biotechnology.
Academic rigor, journalistic flair
Articles on Biotechnology
Displaying 1 - 20 of 88 articles
Research found Big Pharma companies with global reach more likely to abide by environmental standards.
What if plants in the area surrounding a nuclear reactor could act as radiation detectors, with the help of a drone?
The three flu pandemics of the 20th century originated from birds, making it critical to fight bird flu. Breakthroughs in gene-editing chickens show promise for eliminating the disease in the future.
Beyond ordinary consumption, new research finds uses for kola nut in areas like agriculture and health.
Genetically modified crops are increasing yield and food security in developed countries, but in Africa, a lack of adoption is limiting success.
Neuralink might get all the press – but these unsung heroes are pioneering brain-computer interface technology.
The biotech sector uses climate change as an urgent argument for more funding and fewer regulatory hurdles. But the urgency of climate change raises the risk of superficial claims and actions.
Some might argue ‘moral enhancement’ medicine already exists — such as when we take medicine that alters our brain chemistry. Where do we draw a line?
Nigeria can save money spent importing citric acid by producing it from cashew waste.
Record-breaking technology can sequence an entire human genome in a matter of hours. The work could be a lifeline for people suffering from the more than 5,000 known rare genetic diseases.
Scientists are looking for safe new ways to prevent ice from damaging food in frozen storage, which costs consumers billions of dollars a year in wasted food.
The FDA approved Alzheimer’s disease drug aducanumab despite minimal evidence of its efficacy. Whether this decision ultimately hurts or helps patients depends on data researchers don’t yet have.
We may never know whether the pandemic began with a leak at the Wuhan lab. But even the possibility shows we need a universal biosafety code to prevent something similar happening in future.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer’s and other mRNA vaccines.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?
Plant scientists hope to avoid a repeat of the GM foods debate from two decades ago.
Medical innovation is often accelerated in a time of crisis.
Global long-term data simply doesn’t exist for jellyfish, so scientists struggle to predict, track and mitigate their potential effects.
COVID-19 tests rely on a process developed at a biotech company co-founded by a Canadian. Canada’s current testing expertise needs to be channelled to prepare for the next wave, and the next pandemic.
Top contributors
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Assistant Professor of Philosophy, UMass Lowell
-
President, Royal Society of New South Wales
-
Professor of Microbiology, Ladoke Akintola University of Technology, Ogbomoso
-
Doctoral Student in Biochemistry, University of Washington
-
Laureate Professor, The Peter Doherty Institute for Infection and Immunity
-
Adjunct Professor, Murdoch University
-
Professor of Sociology in the School of Social Sciences, Monash University
-
Professor - Emerging Technologies (Stem Cells) at The University of Melbourne and Group Leader - Stem Cell Ethics & Policy at the Murdoch Children's Research Institute, The University of Melbourne
-
Postdoctoral research fellow, University of Sydney
-
Senior lecturer, University of Twente
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Professor of Ocean Leadership, University of Tromsø
-
Professor of Molecular Biology and Genetics, University of Canterbury
-
Assistant Professor, Bond University
